Background
Methods
Study design
Ethical considerations
Data collection
Non-CF bronchiectasis severity assessment tools
Laboratory work-up
Statistical analysis
Results
Controls | Patients | OR (95% CI) | P-value | ||
---|---|---|---|---|---|
N = 30 | N = 30 | ||||
Gender | |||||
Females Males | 16 (53.3%) 14 (46.7%) | 18 (60.0%) 12 (40.0) | - | 0.27* | 0.602 |
Age (years)a | 7.43 ± 2.94 3– 14 | 8.87 ± 3.60 3– 15 | - | -1.68• | 0.097 |
BAL Lipoxin A4 (ng/ml)b | 1675 (536.8– 2542) 370.6– 3876 | 576.9 (147.6– 1501) 68.8– 2352 | - | -3.13† | 0.002 |
ALOX-15 gene polymorphism | |||||
Genotypes, n (%) | |||||
CC CT TT | 14 (46.7%) 8 (26.7%) 8 (26.7%) | 12 (40.0%) 12 (40.0%) 6 (20.0%) | Referent* 1.75 (0.53-5.70) 0.87 (0.23– 3.24) | - 0.353 0.842 | |
Alleles frequency, n (%) | |||||
C T | 36 (60.0%) 24 (40.0%) | 36 (60.0%) 24 (40.0%) | Referent* 1 (0.48 to 2.07) | - 1 |
ALOX-15 Genotypes, n=30 | t | P-value | |||
---|---|---|---|---|---|
CC | CT | TT | |||
N = 12 | N = 12 | N = 6 | |||
BAL Lipoxin A4 levelb(ng/ml) | 546.5 (155.75– 971.05) 68.8– 2045 | 1519 (918.1– 2073) 89– 2352 | 140.6 (132.7– 256) 121.5– 582 | 10.64§ | 0.005 |
BMI Z-score Low Normal | 4 (33.3%) 8 (66.7%) | 6 (50.0%) 6 (50.0%) | 5 (83.3%) 1 (16.7%) | 4* | 0.135 |
Chronic airway colonization No Yes | 4 (33.3%) 8 (66.7%) | 3 (25.0%) 9 (75.0%) | 1 (16.7%) 5 (83.3%) | 0.59* | 0.742 |
Pediatric bronchiectasis severity index Mild Moderate Severe | 2 (16.7%) 8 (66.7%) 2 (16.7%) | 6 (50.0%) 5 (41.7%) 1 (8.3%) | 0 (0.0%) 4 (66.7%) 2 (33.3%) | 6.79* | 0.147 |
PFT affection and severity grading Normal Mild Moderate Severe | 2 (16.7%) 3 (25.0%) 6 (50.0%) 1 (8.3%) | 1 (8.3%) 3 (25.0%) 5 (41.7%) 3 (25.0%) | 1 (16.7%) 1 (16.7%) 3 (50.0%) 1 (16.7%) | 1.62* | 0.951 |
Modified Bhalla scoreb | 9 (4.5 − 13.5) 0– 20 | 9.5 (5.5 − 14) 0– 20 | 11.5 (8 − 15) 5– 15 | 0.513§ | 0.77 |
Variable | Patients |
---|---|
N=30 | |
Duration of illness (years)b | 8 (5 - 9) 2– 14 |
Frequency of admissions due to exacerbations during last yearb | 1.5 (1– 2) 1– 4 |
Pediatric Bronchiectasis severity index, n (%) Mild Moderate Severe | 7 (23.3%) 18 (60%) 5 (16.7%) |
mMRC dyspnea scale, n (%) Grade 0 Grade 1 Grade 2 Grade 3 | 13 (43.3%) 12 (40%) 4 (13.3%) 1 (3.3%) |
BMI for age (kg/m2)a | 14.87 ± 1.99 10.8– 18.6 |
BMI Z-score interpretation Normal Low | 15 (50%) 15 (50%) |
Modified Bhalla scoreb | 9.5 (5– 14) 5– 20 |
Percentage of Lung volume affected by bronchiectasis in HRCT (%)b | 10 (7– 35) 5– 70 |
Spirometry resultsa FVC (% predicted) | 80.74 ± 19.46 22.6– 107 |
FEV1 (% predicted) | 70.94 ± 19.72 25.8– 109 |
FEV1/FVC | 91.36 ± 16.92 56– 115 |
MMEF (% predicted) | 64.32 ± 18.20 34– 92 |
PFT interpretation and severity grading (n=27) Normal Mild Moderate Severe | 4 (14.8%) 7 (25.9%) 11 (40.7%) 5 (18.5%) |
Total BAL cell count (c/mm3)b | 750 (275– 1200) 166– 16,000 |
Predominant BAL cell type Neutrophils Lymphocytes | 23 (76.7%) 7 (23.3%) |
Chronic airway infection No Yes | 9 (30%) 21 (70%) |
Type of organism, n(%) H. influenzae MRSA Pseudomonas aeruginosa Strept. Pneumoniae | 11 (36.7%) 4 (13.3%) 4 (13.3%) 2 (6.7%) |
BAL lipoxin A4 level (n=30) | P-value | ||
---|---|---|---|
Median (IQR) | |||
Gender Female Male | 564.3 (149.4-1408) 576.9 (276.1-1554.5) | 0.38¶ | 0.70 |
Pediatric Bronchiectasis severity index Mild Moderate Severe | 1708 (1477.5– 2186) 576.9(256– 1408) 132.7 (89– 138.9) | 15.52§ | 0.00 |
PFT affection and severity grading Normal Mild Moderate Severe | 1113.95 (578.9– 2336.2) 1408 (476– 1572) 1844 (256– 2302) 576.9 (149.4– 1241) | 8.23§ | 0.04 |
mMRC dyspnea scale Grade 0 Grade 1 Grade 2 Grade 3 | 599.1 (410-1537) 319 (131.1-951.2) 995 (362.1-1413) 1844 | 3.97§ | 0.26 |
Chronic airway colonization Not colonized Colonized | 585.45(274.45– 1690.5) 570.75(149.4– 1418) | 0.23¶ | 0.81 |
Controls | Patients | OR (95% CI) | P-value | |
---|---|---|---|---|
N = 30 | N = 30 | |||
ALOX-15 polymorphism Genotypes | 46.7 / 26.7 / 26.7 | 40.0 / 40.0 / 20.0 | 1.3 (0.37- 4.58) | 0.66 |
Alleles | 60.0/40.0 | 60.0/40.0 | 1 (0.40-2.44) | 1 |